<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlm.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Malar J</journal-id><journal-title>Malaria Journal</journal-title><issn pub-type="epub">1475-2875</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1475-2875-8-247</article-id><article-id pub-id-type="pmid">19874576</article-id><article-id pub-id-type="doi">10.1186/1475-2875-8-247</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>The malaria candidate vaccine liver stage antigen-3 is highly conserved in <italic>Plasmodium falciparum </italic>isolates from diverse geographical areas</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Prieur</surname><given-names>Eric</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>prieur@pasteur.fr</email></contrib><contrib id="A2" corresp="yes" contrib-type="author"><name><surname>Druilhe</surname><given-names>Pierre</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>druilhe@pasteur.fr</email></contrib></contrib-group><aff id="I1"><label>1</label>Biochemical Parasitology Unit, Institut Pasteur, 25 rue du docteur Roux, 75724 Paris, France</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>29</day><month>10</month><year>2009</year></pub-date><volume>8</volume><fpage>247</fpage><lpage>247</lpage><ext-link ext-link-type="uri" xlink:href="http://www.malariajournal.com/content/8/1/247"/><history><date date-type="received"><day>12</day><month>8</month><year>2009</year></date><date date-type="accepted"><day>29</day><month>10</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Prieur and Druilhe; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Prieur and Druilhe; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Prieur Eric prieur@pasteur.fr </dc:author><dc:title> The malaria candidate vaccine liver stage antigen-3 is highly conserved in Plasmodium falciparum isolates from diverse geographical areas </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>Malaria Journal 8(1): 247-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1475-2875(2009)8:1&#x0003c;247&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1475-2875</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>A high level of genetic stability has been formerly identified in segments of the gene coding for the liver stage antigen-3 (LSA-3), a subunit vaccine candidate against <italic>Plasmodium falciparum</italic>. The exploration of <italic>lsa-3 </italic>polymorphisms was extended to the whole sequence of this large antigen in 20 clinical isolates from four geographical areas; Senegal, Comoro islands, Brazil and Thailand.</p></sec><sec sec-type="methods"><title>Methods</title><p>The whole 4680 bp genomic sequence of <italic>lsa-3 </italic>was amplified by polymerase chain reaction and sequenced. The clinical isolate sequences were aligned on the sequence of the laboratory reference <italic>P. falciparum </italic>strain 3D7.</p></sec><sec><title>Results</title><p>The non-repeated sequence of <italic>lsa-3 </italic>was very well conserved with only a few allelic variations scattered along the sequence. Interestingly, a formerly identified immunodominant region, employed for the majority of pre-clinical vaccine development, was totally conserved at the genetic level. The most significant variations observed were in the number and organization of tetrapeptide repeated units, but not in their composition, resulting in different lengths of these repeated regions. The shorter repeated regions were from Brazilian origin. A correlation between the geographical distribution of the parasites with single nucleotide polymorphisms was not detected.</p></sec><sec><title>Conclusion</title><p>The lack of correlation between allelic polymorphisms with a specific transmission pressure suggests that LSA-3 is a structurally constrained molecule. The unusual characteristics of the <italic>lsa-3 </italic>gene make the molecule an interesting candidate for a subunit vaccine against malaria.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>The human malaria parasite <italic>Plasmodium falciparum </italic>is responsible for 300-500 million clinical cases and 1-2 million deaths every year mainly among young African children [<xref ref-type="bibr" rid="B1">1</xref>]. The incidence of malaria among travellers from non-endemic areas is on the rise [<xref ref-type="bibr" rid="B2">2</xref>]. The emergence and spread of resistances against anti-malarial drugs makes the development of a vaccine an urgent need. Na&#x000ef;ve volunteers immunized with radiation-attenuated sporozoites [<xref ref-type="bibr" rid="B3">3</xref>], the form of the parasite injected in the host by a mosquito bite, but not killed parasites, were protected from a challenge with wild-type parasites. This observation suggests that the partial intra-hepatic development of the parasite was necessary to confer protection against the pre-erythrocytic (PE) stages of <italic>P. falciparum </italic>as it has been further verified with recently developed genetically attenuated parasites [<xref ref-type="bibr" rid="B4">4</xref>].</p><p>A subset of twenty parasite antigens expressed during the PE stages were identified by screening an expression library of <italic>P. falciparum </italic>with sera from Europeans living in endemic areas that followed a continuous prophylactic treatment against the pathogenic blood stages of the parasite [<xref ref-type="bibr" rid="B5">5</xref>]. The liver stage antigen-3 (LSA-3) was further selected using discriminating sera of volunteers immunized by radiation-attenuated parasites that were protected against an experimental challenge versus sera from volunteers receiving over-irradiated parasites who were not protected. LSA-3 is a molecule of 1558 amino acids in the strain 3D7 of <italic>P. falciparum</italic>, which includes a majority of non-repetitive sequences and a block of tetrapeptide repeats organized in a-helices [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. These repeats contain the motif E-E-X-hydrophobic amino acid-E-E shared by three other parasite antigens; RESA, Pf11.1 and Ag332 [<xref ref-type="bibr" rid="B8">8</xref>] and recognized by a human monoclonal antibody developed against a parasite of Liberian origin [<xref ref-type="bibr" rid="B9">9</xref>]. LSA-3 is the only molecule of this cross-reacting family of glutamic acid dipeptides-containing antigens that is specifically expressed during the PE stages, both on the surface of sporozoites and in the parasitophorous membrane in the liver cells [<xref ref-type="bibr" rid="B7">7</xref>]. The immunogenicity and protective potential of LSA-3 was established by a series of murine and primate pre-clinical studies [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>]. Its antigenicity was demonstrated by several immuno-epidemiological studies in malaria-exposed populations [<xref ref-type="bibr" rid="B13">13</xref>]. The implication of LSA-3 in the immune response against the PE stages was demonstrated in a murine model where intra-hepatic granulomas of immune cells developed both around the liver forms and around LSA-3 peptide-coated beads that were injected in the portal vein of LSA-3 immunized animals [<xref ref-type="bibr" rid="B14">14</xref>]. Recently, an early serodiagnosis test at the PE stages of <italic>P. falciparum </italic>infection was developed with a recombinant LSA-3 enzyme-linked immunosorbent assay in Burmese patients [<xref ref-type="bibr" rid="B15">15</xref>], and in French troops stationed in Africa (Pradines, Rogier, personal communication).</p><p>The antigens polymorphism represents a major hurdle in the development of vaccines against malaria [<xref ref-type="bibr" rid="B16">16</xref>]. Natural epitope polymorphisms require to include all known alleles in a given vaccine formulation and, in addition can alter the nature of the immune response against the original epitope. Indeed, CSP-specific CD4+ T cells shifted their cytokine production from IFN-&#x003b3; towards the immunosuppressive interleukin-10 in presence of the variant epitope called an altered peptide ligand (APL) [<xref ref-type="bibr" rid="B17">17</xref>].</p><p>Owing to the vaccine potential of LSA-3, the genetic stability of this antigen in clinical isolates from different areas of the world was investigated. The former results obtained on an immunodominant region of LSA-3 were confirmed in this study [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B10">10</xref>] and extended to the whole genetic sequence of <italic>lsa</italic>-3. Strikingly, this molecule appears to be strongly conserved in samples from such distant areas as South America, Africa and South East Asia. The only significant variations consisted in the number of tetrapeptides repeated units, but not in their composition. No obvious geographical pattern of allelic diversity in the <italic>lsa-3 </italic>gene was identified. This characteristic adds arguments in favour of the usefulness of this molecule in a subunit vaccine against malaria.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Genomic material from <italic>Plasmodium falciparum </italic>strains</title><p>Genomic DNA from field isolates of the parasite blood stages was obtained by extraction with the Qiamp DNA blood minikit (Qiagen, USA) on blood samples received from Dielmo in Senegal (n = 7), Brazil (n = 5), Comoro islands (n = 6) and Thailand (n = 2). Nucleotide sequence data reported in this paper are available in the GenBank&#x02122;, EMBL and DDBL databases under the accession numbers GQ222688-GQ22707.</p></sec><sec><title>PCR amplification, cloning and sequencing of <italic>lsa-3</italic></title><p>The complete sequence of <italic>lsa-3 </italic>was obtained by a set of six PCR amplifications (Figure <xref ref-type="fig" rid="F1">1</xref>) with the corresponding PCR primer pairs (Table <xref ref-type="table" rid="T1">1</xref>) designed after the <italic>lsa-3 </italic>sequence found in the strain K1 of <italic>P. falciparum </italic>(GenBank accession number: <ext-link ext-link-type="gen" xlink:href="AJ007010">AJ007010</ext-link>) [<xref ref-type="bibr" rid="B7">7</xref>]. The sequences of the PCR primers originally designed to amplify <italic>lsa-3 </italic>from the strain K1 matched the sequence in the strain 3D7 (GenBank accession number: <ext-link ext-link-type="gen" xlink:href="AE001424">AE001424</ext-link>) [<xref ref-type="bibr" rid="B18">18</xref>]. The PCR reactions were performed on genomic DNA with 2,5 units of AmpliTaq DNA polymerase (Roche, USA) in a final volume of 50 &#x003bc;L of a buffer solution containing 1,5 mM of MgCL<sub>2</sub>, 800 &#x003bc;M of dNTPs and 500 nM of primers. The cycling programme was; 94&#x000b0;C/2 min, [(94&#x000b0;C/15 sec, 57&#x000b0;C/30 sec, 72&#x000b0;C/1 min) &#x000d7; 35], 72&#x000b0;C/2 min, on a PTC-200 thermal cycler (MJ Research). Two sets of PCR amplifications were serially completed on the same samples to prevent ambiguities introduced by the Taq polymerase and thereby confirm any observed mutation. The PCR fragments were purified by electrophoresis in an agarose gel and extracted with the Qiaquick gel extraction kit (Qiagen) before to be introduced in the sequencing plasmid vector pCR4-TOPO. Chemically competent <italic>Escherichia coli </italic>Top 10 bacteria were transformed with an aliquot of the reaction according to the manufacturer instructions (Invitrogen, USA). Plasmids from recombinant bacteria were prepared with the QIAprep miniprep kit (Qiagen, USA) and analysed by restriction enzymatic digestion. The fragment-containing plasmids were sent to a genomics company for sequencing (Cogenics, Meylan, France).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Diagrammatic representation of the <italic>P. falciparum lsa-3 </italic>gene</bold>. The intron is shown as a single line. Sequences coding for the repeated regions I, II and III of the LSA-3 protein are depicted as hatched boxes in exon 2. Fragments amplified by PCR for sequencing are shown below.</p></caption><graphic xlink:href="1475-2875-8-247-1"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Primer pairs used to amplify the <italic>lsa-3 </italic>gene in clinical isolates genomic material.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>PCR fragment</bold></td><td align="left"><bold>Primer forward (5'&#x02192;3')</bold></td><td align="left"><bold>Primer reverse (5'&#x02192;3')</bold></td><td align="left"><bold>PCR length <sup>a</sup></bold></td></tr></thead><tbody><tr><td align="left"><bold>5T</bold></td><td align="left">GTTAGAAAATGACAAATAGTAATTAC</td><td align="left">GTGTTGTTGTTCTTGTTGAACAC</td><td align="left">829</td></tr><tr><td align="left"><bold>Repeats I/II (PCR1)</bold></td><td align="left">GTAAAAAGTGTTCAACAAGAAC</td><td align="left">TTCCTCAGTTTCGATACCACC</td><td align="left">1188</td></tr><tr><td align="left"><bold>Repeats I/II (PCR2)</bold></td><td align="left">GAAAATATTTTGGAGGAAAGTCAAG</td><td align="left">ACTGTCCTTTATTTCCTCAGTTTCG</td><td align="left">1251</td></tr><tr><td align="left"><bold>6.1-6.2</bold></td><td align="left">GGTATCGAAACTGAGGAAATAAAGG</td><td align="left">CATAGCAGGAACATCAACATCCAC</td><td align="left">789</td></tr><tr><td align="left"><bold>C1-C2</bold></td><td align="left">GAAACTGTAACTGAACATGTAGAAC</td><td align="left">CTTCAAGATCTTTTAAATCAGATAC</td><td align="left">745</td></tr><tr><td align="left"><bold>Repeats III</bold></td><td align="left">GATGTCGAAGAAGACAAGATCG</td><td align="left">CTTTTCAATGCGTTTCTCTTTTTGG</td><td align="left">855</td></tr><tr><td align="left"><bold>3T</bold></td><td align="left">GGTGAAGACAAAGATGAAGTTATAG</td><td align="left">GCAATTTTTTATTTTGATTTTTGCGTTC</td><td align="left">665</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>, PCR fragment length in base pairs according to the <italic>lsa-3 </italic>nucleotide sequence in <italic>P. falciparum </italic>strain 3D7.</p></table-wrap-foot></table-wrap></sec><sec><title>Analysis of <italic>lsa-3 </italic>sequences</title><p>The mutations observed after the two sets of PCR amplifications were considered as true polymorphisms whereas mutations observed after a single set of PCR were considered as errors introduced by the Taq polymerase in the amplification step. The sequencing traces were aligned with the SeqMan software (Lasergene, Germany). The derived nucleic and protein sequences were aligned by the MegAlign software (Lasergene, Germany) using the clustalW algorithm and compared to the <italic>lsa-3 </italic>sequence of the <italic>P. falciparum </italic>laboratory strain 3D7 believed to have originated from Africa [<xref ref-type="bibr" rid="B18">18</xref>]. Sequences coding for repeats in the molecule were further aligned manually (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). The sequences corresponding to the short intron (Figure <xref ref-type="fig" rid="F1">1</xref>) were ignored because of the difficulty to reliably amplify this region composed by long strings of A and T nucleotides. Numerations of nucleic and protein sequences were done according to the sequence of <italic>lsa-3 </italic>mRNA and LSA-3 protein of the <italic>P. falciparum </italic>strain 3D7.</p></sec></sec><sec><title>Results and discussion</title><sec><title>Amplification of the <italic>lsa-3 </italic>gene</title><p>The amplification of the gene was achieved by using PCR primers based on the sequence of the previously cloned and fully sequenced <italic>lsa-3 </italic>gene from the strain K1 of <italic>P. falciparum </italic>[<xref ref-type="bibr" rid="B7">7</xref>]. A scheme of the DNA sequence of <italic>lsa-3 </italic>in the generic strain 3D7 is shown in the Figure <xref ref-type="fig" rid="F1">1</xref> with the location and size of the six fragments amplified. The primer pairs (Table <xref ref-type="table" rid="T1">1</xref>) were fully operative on the 20 clinical isolates analysed, even with a stringent annealing temperature of 57&#x000b0;C in the PCR programme.</p></sec><sec><title>Polymorphism of <italic>lsa-3 </italic>at the genetic and protein levels in the non-repeated regions</title><p>The sequences of the full length of the <italic>lsa-3 </italic>gene from the 20 clinical isolates were compared with the published sequence of the laboratory strain 3D7 [<xref ref-type="bibr" rid="B18">18</xref>]. The number of punctual mutations in the sequence coding for the large non-repeated regions of the molecule among the 20 isolates was remarkably low with only 15 single nucleotide polymorphisms (SNPs) out of 3444 base pairs (Figure <xref ref-type="fig" rid="F2">2</xref> and Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>). Five of these were synonymous mutations (33%) whereas 10 were non-synonymous resulting in amino acid changes. This was not unexpected because the full sequencing of <italic>lsa-3 </italic>in the laboratory strain K1 of Thai origin reported six SNPs along the same sequence with two synonymous mutations (33%) [<xref ref-type="bibr" rid="B7">7</xref>]. Moreover, the complete conservation at the genetic level of a sequence coding for an immunodominant region of LSA-3 (<italic>lsa-3</italic><sub>410-775</sub>) that was previously observed in 27 samples from diverse geographical areas [<xref ref-type="bibr" rid="B10">10</xref>] was confirmed in the samples analysed in this study. These frequencies are much lower than in other <italic>P. falciparum </italic>vaccine candidates, such as for example <italic>Pf</italic>AMA1 with 130 non-synonymous mutations out of 1,800 base pairs in 13 Indian samples [<xref ref-type="bibr" rid="B19">19</xref>]. The silent mutation a3882c identified on 12 out of 18 Gambian isolates in a sequence coding for la90 [<xref ref-type="bibr" rid="B20">20</xref>], a peptide recognized by the molecule of the histocompatiblity complex HLA-B53 that is associated with resistance to severe malaria in West Africa was not observed in this study.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Nucleotide and protein sequences of LSA-3 from <italic>P. falciparum </italic>clinical isolates</bold>. The nucleotide sequence of the codons from the reference strain 3D7 with the positions of mutated bases in bold are shown on top. The mutated codons for each clinical isolates are shown below. Sequences corresponding to the repeated sequences I (LSA-3<sub>667-834</sub>), II (LSA-3<sub>835-1758</sub>) and III (LSA-3<sub>3910-4047</sub>) are omitted and represented by three dots. The corresponding amino acid changes resulting from non-synonymous mutations are shown below amino acid residues found in the reference strain 3D7. Identical codons and amino acid residues are represented by hyphens. del denotes a deletion of a codon and the corresponding amino acid.</p></caption><graphic xlink:href="1475-2875-8-247-2"/></fig><p>The singleton variations could be classified in three categories (Figure <xref ref-type="fig" rid="F2">2</xref>). Firstly, singletons observed in a single isolate as a157g in Com 119, t247c in Sen 5522, a1778g in Sen 5514, g2629a in Sen 5505, and c3556t in Sen 5510. Secondly, singletons or group of singletons that were associated with a group of isolates; a1957g, c1998t and g3108a in Bra 1905 and Bra 1884, g2136a in Sen 5510, Sen 5514, Tha 28, Tha 52 and the laboratory strain K1, c4340t in Brazilian isolates 1915, 1882 and 1853. Thirdly, singletons seen in most of the isolates compared to the generic sequence of the strain 3D7, a237t, g2144a, g3108a, a3786g and t4656a. A deletion of the codon gaa (<italic>lsa-3</italic><sub>4121-4122</sub>) was detected in isolates Bra 1905, Bra 1884 and Sen 5522.</p><p>The very low number of SNPs in <italic>lsa-3 </italic>compared to most of the actual malaria candidate vaccines, mainly expressed during the asexual blood stages (ABS), might relate to the PE expression of the protein. The PE antigens are likely less exposed to immunological pressure; Firstly, because of the tremendously lower numbers of PE schizonts as compared to ABS schizonts [<xref ref-type="bibr" rid="B21">21</xref>]. Secondly, once injected in the host blood by an infected mosquito, the sporozoites infect liver cells within a few minutes were they expand and mature inside hepatocytes hidden from antibodies. Finally, the liver maintains a tolerogenic response towards incoming harmless antigens [<xref ref-type="bibr" rid="B22">22</xref>] that might favour the development of the parasite.</p><p>However, the sequence of <italic>msp-3 </italic>coding for the C-terminal region of the merozoite surface protein-3, which is expressed on the surface of merozoites in ABS that are more exposed to immune surveillance, was also remarkably conserved in the same clinical isolates [<xref ref-type="bibr" rid="B23">23</xref>]. These results suggest that, independently of the stage of expression, mechanisms such as structural constraints may drive the genetic stability observed in these antigens and act against the occurrence of mutations.</p></sec><sec><title>Polymorphism of the repeated regions of <italic>lsa-3</italic></title><p>The amplification of the sequence coding for the repeated contiguous regions I and II of LSA-3 showed considerable size variation ranging from 264 nucleotides in the isolate Bra 1853 to 1800 in the K1 strain, respectively (Figure <xref ref-type="fig" rid="F3">3</xref>). The figure <xref ref-type="fig" rid="F4">4</xref> illustrates the corresponding number of tetrapeptide repeats ranging from 22 in the sample Bra 1853 to 150 in the laboratory strain K1.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold><italic>lsa-3 </italic>repeats-coding fragments amplified by PCR showing the size polymorphism of the repeated region I and II</bold>.</p></caption><graphic xlink:href="1475-2875-8-247-3"/></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>Number of tetrapeptide repeated units in the LSA-3 regions I and II of the 20 clinical isolates and the two laboratory strains 3D7 and K1</bold>.</p></caption><graphic xlink:href="1475-2875-8-247-4"/></fig><p>The region I is composed of 14 tetrapeptides in the strain 3D7. Deletions of six tetrapeptides in isolates Bra 1915, Bra 1882 and Bra 1853 and insertions of two tetrapeptides in Com 524 were detected (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). The polymorphism E253G was observed in all strains but not in the strain 3D7. This suggests that the glutamic acid residue at the position 253 of the LSA-3 protein in the strain 3D7 could result from an artificially introduced mutation during the sequencing process of the gene.</p><p>The region II contributes the most to the repeat length heterogeneity between isolates (Figures <xref ref-type="fig" rid="F3">3</xref> and <xref ref-type="fig" rid="F4">4</xref>, Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). Unique tetrapeptides were identified in isolates Sen 5522 (DDGS, VASS, IASS, VDES, IDSS), Sen 5514 (VVEN), Com 119 (VAED, VAEK) and Com 524 (VVPS).</p><p>The region III show little variations compared to the sequence of 3D7 composed of eleven tetrapeptides with only a tetrapeptide deletion in all strains but Tha 28 (no deletion) and Com 119 (two deletions) (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). The repeats composition were identical in all strains apart from two polymorphisms in Sen 5533 changing a tetrapeptide IDED to a unique IEEN.</p><p>The results show that apart from some unique repeats in region II, the composition of most of the tetrapeptide repeats was identical in all strains but solely their number and organisation in the repeated regions varied (Figures <xref ref-type="fig" rid="F3">3</xref> and <xref ref-type="fig" rid="F4">4</xref>, Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>).</p><p>Overall, twenty-two SNPs scattered along the <italic>lsa-3 </italic>sequence (Figure <xref ref-type="fig" rid="F2">2</xref> and Additional files <xref ref-type="supplementary-material" rid="S1">1</xref> and <xref ref-type="supplementary-material" rid="S2">2</xref>) were identified. The polymorphisms in the repeated regions of <italic>lsa-3 </italic>consisted mainly in insertions, deletions and/or reorganizations of sequences coding for the same tetrapeptide units in LSA-3. Although the number of clinical isolates analysed did not allow to draw definitive conclusions, the samples from Brazil seemed to contain the shorter repeated regions whereas samples originating from Thailand with the laboratory strain K1 contained the largest (Figure <xref ref-type="fig" rid="F4">4</xref>). At a time when the polymorphism of LSA-3 had not yet been investigated, it is this particular criterion, of longer length, that led us to choose K1 for molecular characterization of the gene. Hence, the particular length of LSA-3 in K1 is not a surprise, and results now indicate that this size is only due to repeats duplications.</p><p>The strong disparity in the number of repeats in region I and II suggest that the length of this area of the molecule is dispensable for the fitness of the parasite. The repetitive organization of these sequences usually produces B cell epitopes that are immunodominant in other genes, as compared to non-repeated regions. It has been proposed that repeated sequences might act on the intensity and quality of the immune response [<xref ref-type="bibr" rid="B24">24</xref>] and thus contribute to the immune escape of the parasite. A putative escape mechanism could be to divert the immune response from protective epitopes towards these repeated regions of the parasite antigens. However, in the case of LSA-3, detailed immunological studies in hyperendemic areas revealed that B-cell epitopes defined in non-repeated regions were as much the target of antibodies as the repeat blocks [<xref ref-type="bibr" rid="B13">13</xref>]. Hence, in contrast to other genes encoding repeats and particularly Glu-rich repeats, the Glu-rich block of LSA-3 does not seem to be immunodominant. The presence of such repeats in several malarial antigens and the network of cross-reactivity they generate across those molecules have been frequently stressed, however their functions remain poorly understood.</p></sec></sec><sec><title>Conclusion</title><p>LSA-3 is a highly conserved antigen among clinical isolates of <italic>P. falciparum </italic>originating from diverse geographical areas. There is a significant allelic polymorphism solely in the number and organization of the repeated tetrapeptide units. These results question the functionality of the repeated regions of LSA-3 and other genes containing similar structures, and their interaction with the immune system. The paucity of single nucleotide polymorphisms is a positive feature for the development of LSA-3 as a deployable subunit vaccine candidate against malaria for populations living in endemic areas as well as for na&#x000ef;ve travellers. However, the effect of LSA-3 repeats length on the host immune response should be carefully analysed and the vaccine candidate tailored accordingly.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>EP carried out the molecular genetic studies, the sequence alignment and drafted the manuscript. PD participated in the design of the study. Both authors read and approved the final manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>Alignments of amino acid sequences corresponding to the repeated regions of the <italic>Plasmodium falciparum </italic>LSA-3 molecule</bold>. The sequences of LSA-3 from 20 clinical isolates from Senegal, Comoro islands, Brazil, Thailand and the laboratory strain K1 are compared to the one of the generic strain 3D7 (Plasmo dB accession number: PFB0915w).</p></caption><media xlink:href="1475-2875-8-247-S1.RTF" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p><bold>Alignments of amino acid sequences corresponding to the non-repeated regions of the <italic>Plasmodium falciparum </italic>LSA-3 molecule</bold>. The sequences of LSA-3 from 20 clinical isolates from Senegal, Comoro islands, Brazil, Thailand and the laboratory strain K1 are compared to the one of the generic strain 3D7 (Plasmo dB accession number: PFB0915w).</p></caption><media xlink:href="1475-2875-8-247-S2.RTF" mimetype="text" mime-subtype="plain"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>This study was financially supported by a European Community grant number QLK2-CT-2001-01886.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guerra</surname><given-names>CA</given-names></name><name><surname>Gikandi</surname><given-names>PW</given-names></name><name><surname>Tatem</surname><given-names>AJ</given-names></name><name><surname>Noor</surname><given-names>AM</given-names></name><name><surname>Smith</surname><given-names>DL</given-names></name><name><surname>Hay</surname><given-names>SI</given-names></name><name><surname>Snow</surname><given-names>RW</given-names></name></person-group><article-title>The limits and intensity of <italic>Plasmodium falciparum </italic>transmission: implications for malaria control and elimination worldwide</article-title><source>PLoS Med</source><year>2008</year><volume>5</volume><fpage>e38</fpage><pub-id pub-id-type="pmid">18303939</pub-id><pub-id pub-id-type="doi">10.1371/journal.pmed.0050038</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Millet</surname><given-names>JP</given-names></name><name><surname>Garcia de Olalla</surname><given-names>P</given-names></name><name><surname>Carrillo-Santisteve</surname><given-names>P</given-names></name><name><surname>Gascon</surname><given-names>J</given-names></name><name><surname>Trevino</surname><given-names>B</given-names></name><name><surname>Munoz</surname><given-names>J</given-names></name><name><surname>Gomez</surname><given-names>IPJ</given-names></name><name><surname>Cabezos</surname><given-names>J</given-names></name><name><surname>Gonzalez Cordon</surname><given-names>A</given-names></name><name><surname>Cayla</surname><given-names>JA</given-names></name></person-group><article-title>Imported malaria in a cosmopolitan European city: a mirror image of the world epidemiological situation</article-title><source>Malar J</source><year>2008</year><volume>7</volume><fpage>56</fpage><pub-id pub-id-type="pmid">18397524</pub-id><pub-id pub-id-type="doi">10.1186/1475-2875-7-56</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>SL</given-names></name><name><surname>Goh</surname><given-names>LM</given-names></name><name><surname>Luke</surname><given-names>TC</given-names></name><name><surname>Schneider</surname><given-names>I</given-names></name><name><surname>Le</surname><given-names>TP</given-names></name><name><surname>Doolan</surname><given-names>DL</given-names></name><name><surname>Sacci</surname><given-names>J</given-names></name><name><surname>de la Vega</surname><given-names>P</given-names></name><name><surname>Dowler</surname><given-names>M</given-names></name><name><surname>Paul</surname><given-names>C</given-names></name><name><surname>Gordon</surname><given-names>DM</given-names></name><name><surname>Stoute</surname><given-names>JA</given-names></name><name><surname>Church</surname><given-names>LW</given-names></name><name><surname>Sedegah</surname><given-names>M</given-names></name><name><surname>Heppner</surname><given-names>DG</given-names></name><name><surname>Ballou</surname><given-names>WR</given-names></name><name><surname>Richie</surname><given-names>TL</given-names></name></person-group><article-title>Protection of humans against malaria by immunization with radiation-attenuated <italic>Plasmodium falciparum </italic>sporozoites</article-title><source>J Infect Dis</source><year>2002</year><volume>185</volume><fpage>1155</fpage><lpage>1164</lpage><pub-id pub-id-type="pmid">11930326</pub-id><pub-id pub-id-type="doi">10.1086/339409</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Buskirk</surname><given-names>KM</given-names></name><name><surname>O'Neill</surname><given-names>MT</given-names></name><name><surname>De La Vega</surname><given-names>P</given-names></name><name><surname>Maier</surname><given-names>AG</given-names></name><name><surname>Krzych</surname><given-names>U</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Dowler</surname><given-names>MG</given-names></name><name><surname>Sacci</surname><given-names>JB</given-names><suffix>Jr</suffix></name><name><surname>Kangwanrangsan</surname><given-names>N</given-names></name><name><surname>Tsuboi</surname><given-names>T</given-names></name><name><surname>Kneteman</surname><given-names>NM</given-names></name><name><surname>Heppner</surname><given-names>DG</given-names><suffix>Jr</suffix></name><name><surname>Murdock</surname><given-names>BA</given-names></name><name><surname>Mikolajczak</surname><given-names>SA</given-names></name><name><surname>Aly</surname><given-names>AS</given-names></name><name><surname>Cowman</surname><given-names>AF</given-names></name><name><surname>Kappe</surname><given-names>SH</given-names></name></person-group><article-title>Preerythrocytic, live-attenuated <italic>Plasmodium falciparum </italic>vaccine candidates by design</article-title><source>Proc Natl Acad Sci USA</source><year>2009</year><volume>106</volume><fpage>13004</fpage><lpage>13009</lpage><pub-id pub-id-type="pmid">19625622</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0906387106</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marchand</surname><given-names>C</given-names></name><name><surname>Druilhe</surname><given-names>P</given-names></name></person-group><article-title>How to select <italic>Plasmodium falciparum </italic>pre-erythrocytic antigens in an expression library without defined probe</article-title><source>Bull World Health Organ</source><year>1990</year><volume>68</volume><fpage>158</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">1709833</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>DA</given-names></name><name><surname>Wollish</surname><given-names>W</given-names></name><name><surname>Nelson</surname><given-names>RG</given-names></name><name><surname>Leech</surname><given-names>JH</given-names></name><name><surname>Petersen</surname><given-names>C</given-names></name></person-group><article-title><italic>Plasmodium falciparum</italic>: D260, an intraerythrocytic parasite protein, is a member of the glutamic acid dipeptide-repeat family of proteins</article-title><source>Exp Parasitol</source><year>1995</year><volume>81</volume><fpage>79</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">7628570</pub-id><pub-id pub-id-type="doi">10.1006/expr.1995.1095</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Daubersies</surname><given-names>P</given-names></name><name><surname>Thomas</surname><given-names>AW</given-names></name><name><surname>Millet</surname><given-names>P</given-names></name><name><surname>Brahimi</surname><given-names>K</given-names></name><name><surname>Langermans</surname><given-names>JA</given-names></name><name><surname>Ollomo</surname><given-names>B</given-names></name><name><surname>BenMohamed</surname><given-names>L</given-names></name><name><surname>Slierendregt</surname><given-names>B</given-names></name><name><surname>Eling</surname><given-names>W</given-names></name><name><surname>Van Belkum</surname><given-names>A</given-names></name><name><surname>Dubreuil</surname><given-names>G</given-names></name><name><surname>Meis</surname><given-names>JF</given-names></name><name><surname>Gu&#x000e9;rin-Marchand</surname><given-names>C</given-names></name><name><surname>Cayphas</surname><given-names>S</given-names></name><name><surname>Cohen</surname><given-names>J</given-names></name><name><surname>Gras-Masse</surname><given-names>H</given-names></name><name><surname>Druilhe</surname><given-names>P</given-names></name></person-group><article-title>Protection against <italic>Plasmodium falciparum </italic>malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3</article-title><source>Nat Med</source><year>2000</year><volume>6</volume><fpage>1258</fpage><lpage>1263</lpage><pub-id pub-id-type="pmid">11062538</pub-id><pub-id pub-id-type="doi">10.1038/81366</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mattei</surname><given-names>D</given-names></name><name><surname>Berzins</surname><given-names>K</given-names></name><name><surname>Wahlgren</surname><given-names>M</given-names></name><name><surname>Udomsangpetch</surname><given-names>R</given-names></name><name><surname>Perlmann</surname><given-names>P</given-names></name><name><surname>Griesser</surname><given-names>HW</given-names></name><name><surname>Scherf</surname><given-names>A</given-names></name><name><surname>Muller-Hill</surname><given-names>B</given-names></name><name><surname>Bonnefoy</surname><given-names>S</given-names></name><name><surname>Guillotte</surname><given-names/></name><name><surname>Langsley</surname><given-names>G</given-names></name><name><surname>Pereira da Silva</surname><given-names>L</given-names></name><name><surname>Mercereau-Puijalon</surname><given-names>O</given-names></name></person-group><article-title>Cross-reactive antigenic determinants present on different <italic>Plasmodium falciparum </italic>blood-stage antigens</article-title><source>Parasite Immunol</source><year>1989</year><volume>11</volume><fpage>15</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">2467248</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-3024.1989.tb00645.x</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Udomsangpetch</surname><given-names>R</given-names></name><name><surname>Aikawa</surname><given-names>M</given-names></name><name><surname>Berzins</surname><given-names>K</given-names></name><name><surname>Wahlgren</surname><given-names>M</given-names></name><name><surname>Perlmann</surname><given-names>P</given-names></name></person-group><article-title>Cytoadherence of knobless <italic>Plasmodium falciparum</italic>-infected erythrocytes and its inhibition by a human monoclonal antibody</article-title><source>Nature</source><year>1989</year><volume>338</volume><fpage>763</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">2566118</pub-id><pub-id pub-id-type="doi">10.1038/338763a0</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>BenMohamed</surname><given-names>L</given-names></name><name><surname>Gras-Masse</surname><given-names>H</given-names></name><name><surname>Tartar</surname><given-names>A</given-names></name><name><surname>Daubersies</surname><given-names>P</given-names></name><name><surname>Brahimi</surname><given-names>K</given-names></name><name><surname>Bossus</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name><name><surname>Druilhe</surname><given-names>P</given-names></name></person-group><article-title>Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees</article-title><source>Eur J Immunol</source><year>1997</year><volume>27</volume><fpage>1242</fpage><lpage>1253</lpage><pub-id pub-id-type="pmid">9174617</pub-id><pub-id pub-id-type="doi">10.1002/eji.1830270528</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perlaza</surname><given-names>BL</given-names></name><name><surname>Sauzet</surname><given-names>JP</given-names></name><name><surname>Balde</surname><given-names>AT</given-names></name><name><surname>Brahimi</surname><given-names>K</given-names></name><name><surname>Tall</surname><given-names>A</given-names></name><name><surname>Corradin</surname><given-names>G</given-names></name><name><surname>Druilhe</surname><given-names>P</given-names></name></person-group><article-title>Long synthetic peptides encompassing the <italic>Plasmodium falciparum </italic>LSA3 are the target of human B and T cells and are potent inducers of B helper, T helper and cytolytic T cell responses in mice</article-title><source>Eur J Immunol</source><year>2001</year><volume>31</volume><fpage>2200</fpage><lpage>2209</lpage><pub-id pub-id-type="pmid">11449374</pub-id><pub-id pub-id-type="doi">10.1002/1521-4141(200107)31:7&#x0003c;2200::AID-IMMU2200&#x0003e;3.0.CO;2-L</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perlaza</surname><given-names>BL</given-names></name><name><surname>Zapata</surname><given-names>C</given-names></name><name><surname>Valencia</surname><given-names>AZ</given-names></name><name><surname>Hurtado</surname><given-names>S</given-names></name><name><surname>Quintero</surname><given-names>G</given-names></name><name><surname>Sauzet</surname><given-names>JP</given-names></name><name><surname>Brahimi</surname><given-names>K</given-names></name><name><surname>Blanc</surname><given-names>C</given-names></name><name><surname>Ar&#x000e9;valo-Herrera</surname><given-names>M</given-names></name><name><surname>Druilhe</surname><given-names>P</given-names></name><name><surname>Herrera</surname><given-names>S</given-names></name></person-group><article-title>Immunogenicity and protective efficacy of <italic>Plasmodium falciparum </italic>liver-stage Ag-3 in <italic>Aotus lemurinus griseimembra </italic>monkeys</article-title><source>Eur J Immunol</source><year>2003</year><volume>33</volume><fpage>1321</fpage><lpage>1327</lpage><pub-id pub-id-type="pmid">12731057</pub-id><pub-id pub-id-type="doi">10.1002/eji.200323339</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Toure-Balde</surname><given-names>A</given-names></name><name><surname>Perlaza</surname><given-names>BL</given-names></name><name><surname>Sauzet</surname><given-names>JP</given-names></name><name><surname>Ndiaye</surname><given-names>M</given-names></name><name><surname>Aribot</surname><given-names>G</given-names></name><name><surname>Tall</surname><given-names>A</given-names></name><name><surname>Sokhna</surname><given-names>C</given-names></name><name><surname>Rogier</surname><given-names>C</given-names></name><name><surname>Corradin</surname><given-names>G</given-names></name><name><surname>Roussilhon</surname><given-names>C</given-names></name><name><surname>Druilhe</surname><given-names>P</given-names></name></person-group><article-title>Evidence for multiple B- and T-cell epitopes in Plasmodium falciparum liver-stage antigen 3</article-title><source>Infect Immun</source><year>2009</year><volume>77</volume><fpage>1189</fpage><lpage>1196</lpage><pub-id pub-id-type="pmid">19139199</pub-id><pub-id pub-id-type="doi">10.1128/IAI.00780-07</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hebert</surname><given-names>A</given-names></name><name><surname>Sauzet</surname><given-names>JP</given-names></name><name><surname>Lebastard</surname><given-names>M</given-names></name><name><surname>Ungeheuer</surname><given-names>MN</given-names></name><name><surname>Ave</surname><given-names>P</given-names></name><name><surname>Huerre</surname><given-names>M</given-names></name><name><surname>Druilhe</surname><given-names>P</given-names></name></person-group><article-title>Analysis of intra-hepatic peptide-specific cell recruitment in mice immunised with <italic>Plasmodium falciparum </italic>antigens</article-title><source>J Immunol Methods</source><year>2003</year><volume>275</volume><fpage>123</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">12667676</pub-id><pub-id pub-id-type="doi">10.1016/S0022-1759(03)00017-6</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>HW</given-names></name><name><surname>Moon</surname><given-names>SU</given-names></name><name><surname>Ryu</surname><given-names>HS</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Cho</surname><given-names>SH</given-names></name><name><surname>Chung</surname><given-names>GT</given-names></name><name><surname>Lin</surname><given-names>K</given-names></name><name><surname>Na</surname><given-names>BK</given-names></name><name><surname>Kong</surname><given-names>Y</given-names></name><name><surname>Chung</surname><given-names>KS</given-names></name><name><surname>Kim</surname><given-names>TS</given-names></name></person-group><article-title>Usefulness of the recombinant liver stage antigen-3 for an early serodiagnosis of <italic>Plasmodium falciparum </italic>infection</article-title><source>Korean J Parasitol</source><year>2006</year><volume>44</volume><fpage>49</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">16514282</pub-id><pub-id pub-id-type="doi">10.3347/kjp.2006.44.1.49</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahajan</surname><given-names>RC</given-names></name><name><surname>Farooq</surname><given-names>U</given-names></name><name><surname>Dubey</surname><given-names>ML</given-names></name><name><surname>Malla</surname><given-names>N</given-names></name></person-group><article-title>Genetic polymorphism in <italic>Plasmodium falciparum </italic>vaccine candidate antigens</article-title><source>Indian J Pathol Microbiol</source><year>2005</year><volume>48</volume><fpage>429</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">16366089</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Plebanski</surname><given-names>M</given-names></name><name><surname>Flanagan</surname><given-names>KL</given-names></name><name><surname>Lee</surname><given-names>EA</given-names></name><name><surname>Reece</surname><given-names>WH</given-names></name><name><surname>Hart</surname><given-names>K</given-names></name><name><surname>Gelder</surname><given-names>C</given-names></name><name><surname>Gillespie</surname><given-names>G</given-names></name><name><surname>Pinder</surname><given-names>M</given-names></name><name><surname>Hill</surname><given-names>AV</given-names></name></person-group><article-title>Interleukin 10-mediated immunosuppression by a variant CD4 T cell epitope of <italic>Plasmodium falciparum</italic></article-title><source>Immunity</source><year>1999</year><volume>10</volume><fpage>651</fpage><lpage>660</lpage><pub-id pub-id-type="pmid">10403640</pub-id><pub-id pub-id-type="doi">10.1016/S1074-7613(00)80064-3</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gardner</surname><given-names>MJ</given-names></name><name><surname>Hall</surname><given-names>N</given-names></name><name><surname>Fung</surname><given-names>E</given-names></name><name><surname>White</surname><given-names>O</given-names></name><name><surname>Berriman</surname><given-names>M</given-names></name><name><surname>Hyman</surname><given-names>RW</given-names></name><name><surname>Carlton</surname><given-names>JM</given-names></name><name><surname>Pain</surname><given-names>A</given-names></name><name><surname>Nelson</surname><given-names>KE</given-names></name><name><surname>Bowman</surname><given-names>S</given-names></name><name><surname>Paulsen</surname><given-names>IT</given-names></name><name><surname>James</surname><given-names>K</given-names></name><name><surname>Eisen</surname><given-names>JA</given-names></name><name><surname>Rutherford</surname><given-names>K</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name><name><surname>Craig</surname><given-names>A</given-names></name><name><surname>Kyes</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>MS</given-names></name><name><surname>Nene</surname><given-names>V</given-names></name><name><surname>Shallom</surname><given-names>SJ</given-names></name><name><surname>Suh</surname><given-names>B</given-names></name><name><surname>Peterson</surname><given-names>J</given-names></name><name><surname>Angiuoli</surname><given-names>S</given-names></name><name><surname>Pertea</surname><given-names>M</given-names></name><name><surname>Allen</surname><given-names>J</given-names></name><name><surname>Selengut</surname><given-names>J</given-names></name><name><surname>Haft</surname><given-names>D</given-names></name><name><surname>Mather</surname><given-names>MW</given-names></name><name><surname>Vaidya</surname><given-names>AB</given-names></name><name><surname>Martin</surname><given-names>DM</given-names></name><name><surname>Fairlamb</surname><given-names>AH</given-names></name><name><surname>Fraunholz</surname><given-names>MJ</given-names></name><name><surname>Roos</surname><given-names>DS</given-names></name><name><surname>Ralph</surname><given-names>SA</given-names></name><name><surname>McFadden</surname><given-names>GI</given-names></name><name><surname>Cummings</surname><given-names>LM</given-names></name><name><surname>Subramanian</surname><given-names>GM</given-names></name><name><surname>Mungall</surname><given-names>C</given-names></name><name><surname>Venter</surname><given-names>JC</given-names></name><name><surname>Carucci</surname><given-names>DJ</given-names></name><name><surname>Hoffman</surname><given-names>SL</given-names></name><name><surname>Newbold</surname><given-names>C</given-names></name><name><surname>Davis</surname><given-names>RW</given-names></name><name><surname>Fraser</surname><given-names>CM</given-names></name><name><surname>Barrell</surname><given-names>B</given-names></name></person-group><article-title>Genome sequence of the human malaria parasite <italic>Plasmodium falciparum</italic></article-title><source>Nature</source><year>2002</year><volume>419</volume><fpage>498</fpage><lpage>511</lpage><pub-id pub-id-type="pmid">12368864</pub-id><pub-id pub-id-type="doi">10.1038/nature01097</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rajesh</surname><given-names>V</given-names></name><name><surname>Singamsetti</surname><given-names>VK</given-names></name><name><surname>Vidya</surname><given-names>S</given-names></name><name><surname>Gowrishankar</surname><given-names>M</given-names></name><name><surname>Elamaran</surname><given-names>M</given-names></name><name><surname>Tripathi</surname><given-names>J</given-names></name><name><surname>Radhika</surname><given-names>NB</given-names></name><name><surname>Kochar</surname><given-names>D</given-names></name><name><surname>Ranjan</surname><given-names>A</given-names></name><name><surname>Roy</surname><given-names>SK</given-names></name><name><surname>Das</surname><given-names>A</given-names></name></person-group><article-title><italic>Plasmodium falciparum</italic>: genetic polymorphism in apical membrane antigen-1 gene from Indian isolates</article-title><source>Exp Parasitol</source><year>2008</year><volume>119</volume><fpage>144</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">18343371</pub-id><pub-id pub-id-type="doi">10.1016/j.exppara.2008.01.019</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aidoo</surname><given-names>M</given-names></name><name><surname>Lalvani</surname><given-names>A</given-names></name><name><surname>Gilbert</surname><given-names>SC</given-names></name><name><surname>Hu</surname><given-names>JT</given-names></name><name><surname>Daubersies</surname><given-names>P</given-names></name><name><surname>Hurt</surname><given-names>N</given-names></name><name><surname>Whittle</surname><given-names>HC</given-names></name><name><surname>Druihle</surname><given-names>P</given-names></name><name><surname>Hill</surname><given-names>AV</given-names></name></person-group><article-title>Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3</article-title><source>Infect Immun</source><year>2000</year><volume>68</volume><fpage>227</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">10603392</pub-id><pub-id pub-id-type="doi">10.1128/IAI.68.1.227-232.2000</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vaughan</surname><given-names>AM</given-names></name><name><surname>Aly</surname><given-names>AS</given-names></name><name><surname>Kappe</surname><given-names>SH</given-names></name></person-group><article-title>Malaria parasite pre-erythrocytic stage infection: gliding and hiding</article-title><source>Cell Host Microbe</source><year>2008</year><volume>4</volume><fpage>209</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">18779047</pub-id><pub-id pub-id-type="doi">10.1016/j.chom.2008.08.010</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knolle</surname><given-names>PA</given-names></name><name><surname>Gerken</surname><given-names>G</given-names></name></person-group><article-title>Local control of the immune response in the liver</article-title><source>Immunol Rev</source><year>2000</year><volume>174</volume><fpage>21</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">10807504</pub-id><pub-id pub-id-type="doi">10.1034/j.1600-0528.2002.017408.x</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roussilhon</surname><given-names>C</given-names></name><name><surname>Oeuvray</surname><given-names>C</given-names></name><name><surname>Muller-Graf</surname><given-names>C</given-names></name><name><surname>Tall</surname><given-names>A</given-names></name><name><surname>Rogier</surname><given-names>C</given-names></name><name><surname>Trape</surname><given-names>JF</given-names></name><name><surname>Theisen</surname><given-names>M</given-names></name><name><surname>Balde</surname><given-names>A</given-names></name><name><surname>Perignon</surname><given-names>JL</given-names></name><name><surname>Druilhe</surname><given-names>P</given-names></name></person-group><article-title>Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3</article-title><source>PLoS Med</source><year>2007</year><volume>4</volume><fpage>e320</fpage><pub-id pub-id-type="pmid">18001147</pub-id><pub-id pub-id-type="doi">10.1371/journal.pmed.0040320</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramasamy</surname><given-names>R</given-names></name></person-group><article-title>Molecular basis for evasion of host immunity and pathogenesis in malaria</article-title><source>Biochim Biophys Acta</source><year>1998</year><volume>1406</volume><fpage>10</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">9545516</pub-id></citation></ref></ref-list></back></article> 